BRPI0819914A2 - método para tratar uma doença, uso de um composto e seus sais farmaceuticamente aceitáveis, e, composto. - Google Patents

método para tratar uma doença, uso de um composto e seus sais farmaceuticamente aceitáveis, e, composto.

Info

Publication number: BRPI0819914A2
Authority: BR; Brazil
Prior art keywords: compound; disease; treating; pharmaceutically acceptable; acceptable salts
Prior art date: 2007-12-14

Application number

BRPI0819914A

Other languages

English (en)

Inventor

Aneil Batra

Eva Elstrup Jensen

Jin Chon

Nanco Hefting

Silke Miller

Original Assignee

Lundbeck & Co As H

Takeda Pharmaceuticals North America Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-14

Filing date

2008-12-11

Publication date

2016-05-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40285887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819914(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-11 Application filed by Lundbeck & Co As H, Takeda Pharmaceuticals North America Inc filed Critical Lundbeck & Co As H

2016-05-17 Publication of BRPI0819914A2 publication Critical patent/BRPI0819914A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0819914A 2007-12-14 2008-12-11 método para tratar uma doença, uso de um composto e seus sais farmaceuticamente aceitáveis, e, composto. BRPI0819914A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200701791		2007-12-14
DKPA200701798		2007-12-17
PCT/DK2008/050302 WO2009076962A1 (en)	2007-12-14	2008-12-11	Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Publications (1)

Publication Number	Publication Date
BRPI0819914A2 true BRPI0819914A2 (pt)	2016-05-17

Family

ID=40285887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819914A BRPI0819914A2 (pt)	2007-12-14	2008-12-11	método para tratar uma doença, uso de um composto e seus sais farmaceuticamente aceitáveis, e, composto.

Country Status (18)

Country	Link
US (3)	US20110053978A1 (pt)
EP (1)	EP2231154A1 (pt)
JP (1)	JP2011506353A (pt)
KR (1)	KR20100092956A (pt)
CN (1)	CN102202666A (pt)
AR (1)	AR069904A1 (pt)
AU (1)	AU2008338059A1 (pt)
BR (1)	BRPI0819914A2 (pt)
CA (1)	CA2708786A1 (pt)
CL (1)	CL2008003709A1 (pt)
CO (1)	CO6290669A2 (pt)
EA (1)	EA201070737A1 (pt)
IL (1)	IL205965A0 (pt)
MX (1)	MX2010005795A (pt)
NZ (1)	NZ586010A (pt)
SG (1)	SG185984A1 (pt)
TW (1)	TW200938194A (pt)
WO (1)	WO2009076962A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE540941T1 (de)	2006-06-16	2012-01-15	Lundbeck & Co As H	1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
TWI432194B (zh) *	2007-03-20	2014-04-01	Lundbeck & Co As H	４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
GEP20166487B (en) *	2010-04-30	2016-06-10	Takeda Pharmaceutical	Enteric tablet
CN104710345B (zh) *	2013-12-17	2017-09-05	江苏恩华药业股份有限公司	用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CN104120177A (zh) *	2014-06-11	2014-10-29	杭州艾迪康医学检验中心有限公司	检测5-httlpr片段多态性的方法和引物
WO2019008484A1 (en) *	2017-07-03	2019-01-10	Suven Life Sciences Limited	NEW USES OF A PURE 5-HT6 RECEPTOR ANTAGONIST

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DK1626720T3 (da) *	2003-04-04	2008-12-01	Lundbeck & Co As H	4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
CA2656057C (en) *	2006-06-16	2012-10-02	H. Lundbeck A/S	Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) *	2007-03-20	2014-04-01	Lundbeck & Co As H	４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
HRP20140044T1 (hr) *	2007-06-15	2014-02-14	H. Lundbeck A/S	4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs)

2008
- 2008-12-02 TW TW097146699A patent/TW200938194A/zh unknown
- 2008-12-11 CA CA2708786A patent/CA2708786A1/en not_active Abandoned
- 2008-12-11 CN CN2008801203913A patent/CN102202666A/zh active Pending
- 2008-12-11 MX MX2010005795A patent/MX2010005795A/es not_active Application Discontinuation
- 2008-12-11 BR BRPI0819914A patent/BRPI0819914A2/pt not_active IP Right Cessation
- 2008-12-11 US US12/747,403 patent/US20110053978A1/en not_active Abandoned
- 2008-12-11 AU AU2008338059A patent/AU2008338059A1/en not_active Abandoned
- 2008-12-11 KR KR1020107013095A patent/KR20100092956A/ko not_active Withdrawn
- 2008-12-11 WO PCT/DK2008/050302 patent/WO2009076962A1/en not_active Ceased
- 2008-12-11 EP EP08862439A patent/EP2231154A1/en not_active Withdrawn
- 2008-12-11 EA EA201070737A patent/EA201070737A1/ru unknown
- 2008-12-11 JP JP2010537257A patent/JP2011506353A/ja active Pending
- 2008-12-11 SG SG2012083010A patent/SG185984A1/en unknown
- 2008-12-11 NZ NZ586010A patent/NZ586010A/xx not_active IP Right Cessation
- 2008-12-12 CL CL2008003709A patent/CL2008003709A1/es unknown
- 2008-12-12 AR ARP080105414A patent/AR069904A1/es not_active Application Discontinuation
2010
- 2010-05-25 IL IL205965A patent/IL205965A0/en unknown
- 2010-06-11 CO CO10070917A patent/CO6290669A2/es not_active Application Discontinuation
2014
- 2014-05-16 US US14/279,504 patent/US20140296290A1/en not_active Abandoned
2016
- 2016-05-03 US US15/145,102 patent/US20170087138A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2009076962A1 (en)	2009-06-25
NZ586010A (en)	2012-08-31
US20110053978A1 (en)	2011-03-03
JP2011506353A (ja)	2011-03-03
US20140296290A1 (en)	2014-10-02
CO6290669A2 (es)	2011-06-20
TW200938194A (en)	2009-09-16
CA2708786A1 (en)	2009-06-25
CL2008003709A1 (es)	2010-01-15
EP2231154A1 (en)	2010-09-29
AU2008338059A1 (en)	2009-06-25
US20170087138A1 (en)	2017-03-30
SG185984A1 (en)	2012-12-28
IL205965A0 (en)	2010-11-30
AR069904A1 (es)	2010-03-03
MX2010005795A (es)	2010-08-31
EA201070737A1 (ru)	2010-12-30
KR20100092956A (ko)	2010-08-23
CN102202666A (zh)	2011-09-28

Similar Documents

Publication	Publication Date	Title
NO2025029I1 (no)	2025-06-13	Entrectinib or isomers, tautomers, or pharmaceutically acceptable salts therof - forlenget
BRPI0814688A2 (pt)	2017-06-06	composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica
BR112012003578A2 (pt)	2015-09-08	composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal.
BRPI0821274A2 (pt)	2017-06-13	composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0910734A2 (pt)	2015-09-29	composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0815057A2 (pt)	2015-07-28	Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0814503A2 (pt)	2017-05-16	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0815894A2 (pt)	2015-02-24	Composição farmacêutica, uso da mesma, e, sais farmaceuticamente aceitáveis de um composto.
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0922566A2 (pt)	2017-03-28	polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0818193A2 (pt)	2017-12-12	composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0820474A2 (pt)	2017-05-23	método de tratamento de uma doença, uso de composto, e, composto
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.

Legal Events

Date	Code	Title	Description
2016-06-21	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2016-10-11	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.